Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0455 Transporter Info
Gene Name SLC6A3
Transporter Name Sodium-dependent dopamine transporter
Gene ID
6531
UniProt ID
Q01959
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Cocaine

            6 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine inhibits the transportation of Dopamine by SLC6A3 [1]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Cocaine inhibits the transportation of Dopamine by SLC6A3 [2] , [3]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1

  DT Modulation 3

 Cocaine inhibits the transportation of Mazindol by SLC6A3 [4]

Affected Drug/Substrate

 Mazindol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 4

 Cocaine inhibits the transportation of RTI-55 by SLC6A3 [4] , [5]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 5

 Cocaine inhibits the activity of SLC6A3 [6] , [7]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 6

 Cocaine inhibits the activity of SLC6A3 [2] , [3]

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1

  Mazindol

            5 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mazindol inhibits the transportation of Mazindol by SLC6A3 [4]

Affected Drug/Substrate

 Mazindol Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Mazindol inhibits the transportation of RTI-55 by SLC6A3 [4]

Affected Drug/Substrate

 RTI-55 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 3

 Mazindol inhibits the transportation of WIN-35428 by SLC6A3 [8]

Affected Drug/Substrate

 WIN-35428 Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-DAT1

  DT Modulation 4

 Mazindol inhibits the activity of SLC6A3 [6]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 5

 Mazindol inhibits the activity of SLC6A3 [9] , [10] , [11]

Cell System

 Chinese hamster ovary (CHO) cells-DAT1

  Duloxetine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Duloxetine inhibits the transportation of Dopamine by SLC6A3 [12]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Duloxetine inhibits the transportation of WIN-35428 by SLC6A3 [15]

Affected Drug/Substrate

 WIN-35428 Modulation Type Inhibition

  DT Modulation 3

 Duloxetine inhibits the activity of SLC6A3 [16] , [17] , [18] , [19]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Reboxetine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Reboxetine inhibits the transportation of Dopamine by SLC6A3 [12]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Reboxetine inhibits the transportation of WIN-35428 by SLC6A3 [14]

Affected Drug/Substrate

 WIN-35428 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 3

 Reboxetine inhibits the activity of SLC6A3 [18]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Modafinil

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Modafinil inhibits the transportation of Uridine by SLC6A3 [13]

Affected Drug/Substrate

 Uridine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1

  DT Modulation 2

 Modafinil inhibits the activity of SLC6A3 [2]

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1

  DT Modulation 3

 Modafinil modulates the activity of SLC6A3 [20]

  Fluoxetine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fluoxetine inhibits the transportation of Dopamine by SLC6A3 [1] , [21] , [22]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Fluoxetine inhibits the activity of SLC6A3 [24] , [25] , [26]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Venlafaxine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Venlafaxine inhibits the transportation of Dopamine by SLC6A3 [1] , [22]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Venlafaxine inhibits the activity of SLC6A3 [19] , [26]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Methylphenidate

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylphenidate inhibits the activity of SLC6A3 [23]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  DT Modulation 2

 Methylphenidate blocks the activity of SLC6A3 [27]

  Decitabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decitabine inhibits DNA methyltransferase, which then enhances the expression of SLC6A3 via downregulating the promoter hypermethylation level [28]

Cell System

 Human dopaminergic neuroblastoma cell line (SH-SY-5Y)

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic acid inhibits histone deacetylase, which then enhances the expression of SLC6A3 via increasing the histone acethylation level [29]

Cell System

 Model organism in vivo (rat)

  4-Fluoroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoroamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 3.7 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  4-Fluoromethamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoromethamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 7.7 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  alpha-Pyrrolidinopentiophenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 alpha-Pyrrolidinopentiophenone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.04 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Amphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 1.3 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Ephedrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ephedrine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 46 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Methamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methamphetamine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 1.1 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Citalopram

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Citalopram inhibits the transportation of Dopamine by SLC6A3 [31]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1

  Amitriptyline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitriptyline inhibits the transportation of Dopamine by SLC6A3 [1]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Dextroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextroamphetamine inhibits the transportation of Dopamine by SLC6A3 [1]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Dopamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dopamine inhibits the activity of SLC6A3 [32]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Bupropion

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bupropion inhibits the activity of SLC6A3 [7]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Dexmethylphenidate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dexmethylphenidate inhibits the activity of SLC6A3 [33] , [34]

Cell System

 N2A neuroblastoma cells-DAT1

  Milnacipran

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Milnacipran inhibits the activity of SLC6A3 [18]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Desvenlafaxine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desvenlafaxine inhibits the activity of SLC6A3 [19]

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Armodafinil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Armodafinil inhibits the activity of SLC6A3 [2]

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)7-DAT1

  Permethrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Permethrin affects the activity of SLC6A3 [35]

  Calcitriol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Calcitriol increases the expression of SLC6A3 [36]

  Testosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Testosterone increases the expression of SLC6A3 [36]

  Carbamazepine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carbamazepine affects the expression of SLC6A3 [37]

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat increases the expression of SLC6A3 [38]

  Ioflupane I-123

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ioflupane I-123 modulates the activity of SLC6A3 [40]

  Altropane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Altropane inhibits the activity of SLC6A3 [41]

  Paroxetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Paroxetine inhibits the activity of SLC6A3 [42]

  Haloperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Haloperidol inhibits the activity of SLC6A3 [43]

  Clomipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clomipramine inhibits the activity of SLC6A3 [44]

  Dimethyl fumarate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dimethyl fumarate induces the activity of SLC6A3 [45]

Drug Marketed but not Approved by US FDA

  Rotenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rotenone inhibits the expression of SLC6A3 [39]

Drug in Phase 2/3 Trial

  Sodium butyrate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium butyrate inhibits histone deacetylase, which then enhances the expression of SLC6A3 via increasing the histone acethylation level [28]

Cell System

 Human embryonic kidney 293 cells (HEK293)

Drug in Phase 3 Trial

  Dasotraline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dasotraline inhibits the activity of SLC6A3 [51]

  Amitifadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitifadine inhibits the activity of SLC6A3 [53] , [54] , [55]

Drug in Phase 2 Trial

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bisphenol A increases the expression of SLC6A3 [49]

  Amfetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amfetamine inhibits the activity of SLC6A3 [52]

  DOV 21947

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 DOV 21947 inhibits the activity of SLC6A3 [56]

Drug in Phase 1 Trial

  Butyrate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Butyrate increases the expression of SLC6A3 [47]

Drug in Preclinical Test

  AM-2282

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 AM-2282 increases the activity of SLC6A3 [48]

Investigative Drug

  3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.11 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.53 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Methcathinone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methcathinone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 2.4 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Methylenedioxypyrovalerone (MDPV)

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.05 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Pyrovalerone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrovalerone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.07 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

Drug Withdrawn

  Naphyrone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naphyrone inhibits the transportation of Serotonin by SLC6A3 (IC50 = 0.22 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

Natural Product

  4-Fluoroephedrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 4-Fluoroephedrine inhibits the transportation of Serotonin by SLC6A3 (IC50 = 163 microM) [30]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-DAT1

  Deguelin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Deguelin inhibits the expression of SLC6A3 [39]

Environmental toxicant

  Zinc

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zinc inhibits the activity of SLC6A3 [46]

Pesticide/Insecticide

  Decamethrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decamethrin affects the activity of SLC6A3 [35]

Health and Environmental Toxicant

  1-methyl-4-phenylpyridinium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-methyl-4-phenylpyridinium inhibits the expression of SLC6A3 [50]
References
1 An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3411-5.
2 Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors. J Med Chem. 2016 Dec 8;59(23):10676-10691.
3 Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
4 Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123.
5 Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors. J Med Chem. 1999 Sep 9;42(18):3647-56.
6 Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
7 Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
8 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. J Med Chem. 2009 Sep 24;52(18):5703-11.
9 Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5029-32.
10 Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J Med Chem. 2010 Jun 10;53(11):4511-21.
11 Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). J Med Chem. 2011 Oct 13;54(19):6824-31.
12 Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2562-6.
13 Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues. J Med Chem. 2014 Feb 13;57(3):1000-13.
14 [4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1795-8.
15 Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6.
16 Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
17 N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5078-81.
18 A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1456-61.
19 Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett. 2013 May 7;4(6):560-4.
20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
21 Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5515-8.
22 Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3234-7.
23 Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
24 Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
25 Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem. 2009 Mar 26;52(6):1530-9.
26 Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3--Oxyazetidine. ACS Med Chem Lett. 2014 Jul 10;5(9):999-1004.
27 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
28 The correlation between DNA methylation and transcriptional expression of human dopamine transporter in cell lines. Neurosci Lett. 2018 Jan 1;662:91-97.
29 Effects of atomoxetine on hyper-locomotive activity of the prenatally valproate-exposed rat offspring. Biomol Ther (Seoul). 2014 Sep;22(5):406-13.
30 Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76.
31 A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett. 2013 Jan 1;23(1):323-6.
32 Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.
33 Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling. Bioorg Med Chem. 2011 Jan 1;19(1):504-12.
34 Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (+-)-threo-Methylphenidate. ACS Med Chem Lett. 2012 May 10;3(5):378-382.
35 Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97.
36 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
37 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
38 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
39 Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615.
40 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
41 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
42 Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem. 2005 Sep 22;48(19):6023-34.
43 Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4294-7.
44 Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
45 The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-kB/Nuclear Transcription Factor Related to NF-E2. Antioxid Redox Signal. 2017 Sep 10;27(8):453-471.
46 Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol. 2006 Aug;70(2):542-8.
47 Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem. 2007 Apr;101(2):377-88.
48 The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur J Neurosci. 2008 Dec;28(12):2459-73.
49 Adverse effects of bisphenol A (BPA) on the dopamine system in two distinct cell models and corpus striatum of the Sprague-Dawley rat. J Toxicol Environ Health A. 2016;79(20):912-24.
50 Curcumin Protects an SH-SY5Y Cell Model of Parkinson's Disease Against Toxic Injury by Regulating HSP90. Cell Physiol Biochem. 2018;51(2):681-691.
51 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
52 Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment. CNS Drugs. 2010 Sep;24(9):721-8.
53 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
54 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem. 2010 Mar 25;53(6):2534-51.
55 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
56 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors. Bioorg Med Chem. 2011 Jun 1;19(11):3451-61.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.